Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2020 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.
Moreira GA, Caetano MMM, do Vale JA, de Paiva JC, Gonçalves VHS, Almeida AA, Silva LVG, Martim FRG, de Andrade Barros MV, Guimarães GR, de Oliveira Santos L, de Souza APM, Machado-Neves M, Teixeira RR, Silva-Júnior A, Fietto JLR, Boroni M, de Oliveira LL, Bressan GC. Moreira GA, et al. Among authors: de souza apm. Biochem Pharmacol. 2022 Sep;203:115161. doi: 10.1016/j.bcp.2022.115161. Epub 2022 Jul 2. Biochem Pharmacol. 2022. PMID: 35787994 Free article.
Effect of the topical administration of N-(2-(4-bromophenylamino)-5-(trifluoromethyl)phenyl)nicotinamide compound in a murine subcutaneous melanoma model.
Vale JAD, de Souza APM, Lima GDA, Gonçalves VHS, Moreira GA, Barros MVA, Pereira WL, Merchid NCLE, Fietto JLR, Bressan GC, Teixeira RR, Machado-Neves M. Vale JAD, et al. Among authors: de souza apm. Anticancer Drugs. 2020 Aug;31(7):718-727. doi: 10.1097/CAD.0000000000000944. Anticancer Drugs. 2020. PMID: 32568827
Immunomodulatory activity of trifluoromethyl arylamides derived from the SRPK inhibitor SRPIN340 and their potential use as vaccine adjuvant.
Mendes FC, de Paiva JC, da Silva EQG, Santos MR, de Almeida Lima GD, Moreira GA, Silva LVG, de Melo Agripino J, de Souza APM, de Oliveira Mendes TA, Machado-Neves M, Teixeira RR, Silva-Júnior A, Fietto JLR, de Oliveira LL, Bressan GC. Mendes FC, et al. Among authors: de souza apm. Life Sci. 2022 Oct 15;307:120849. doi: 10.1016/j.lfs.2022.120849. Epub 2022 Aug 1. Life Sci. 2022. PMID: 35926588 Free article.
First evidence of a serine arginine protein kinase (SRPK) in leishmania braziliensis and its potential as therapeutic target.
Pimentel DC, Leopoldo JR, Teixeira LF, Barros MVA, de Souza APM, Onofre TS, de Carvalho RL, Machado SA, Messias IG, Pinto CCS, Poleto MD, Diogo MA, Mariotini-Moura C, Bressan GC, Teixeira RR, Fietto JLR, Vasconcellos RS. Pimentel DC, et al. Among authors: de souza apm. Acta Trop. 2023 Feb;238:106801. doi: 10.1016/j.actatropica.2022.106801. Epub 2022 Dec 20. Acta Trop. 2023. PMID: 36563831
Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.
Siqueira RP, Caetano MMM, de Souza LÂ, Dos Passos PMS, Simaroli NB, Barros MVA, de Souza APM, de Oliveira LL, Silva-Júnior A, Fietto JLR, Teixeira RR, Teixeira FR, Bressan GC. Siqueira RP, et al. Among authors: de souza apm. Toxicol In Vitro. 2020 Jun;65:104777. doi: 10.1016/j.tiv.2020.104777. Epub 2020 Jan 18. Toxicol In Vitro. 2020. PMID: 31962201 Free article.